Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 9/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25601716 | 1.00 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL13964494 | 1.00 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL3462484 | 0.87 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL3096508 | 0.87 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL2329376 | 0.87 | CA1 (0.42) | CA1CA2CA7CTSKATM | |
| SCHEMBL2104058 | 0.87 | CYP2D6 (0.45) | CA1CA2CA7CTSKATM | |
| SCHEMBL4671387 | 0.87 | CYP2D6 (0.45) | CA1CA2CA7CTSKATM | |
| SCHEMBL4671380 | 0.87 | CYP2D6 (0.45) | CA1CA2CA7CTSKATM | |
| SCHEMBL23833082 | 0.85 | CA1 (0.41) | CA1CA2CA7CTSKATM | |
| SCHEMBL14471734 | 0.85 | CA1 (0.41) | CA1CA2CA7CTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099978-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | INCYTE CORPORATION | 2018-04-12 | — | — | US | disclosed |
| US-9802957-B2 | Processes of preparing a JAK1 inhibitor and new forms thereto | INCYTE CORPORATION (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150344497-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | INCYTE CORPORATION (US) | 2015-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099978-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | JAK1, JAK2, JAK3 | CA1 4464/4885CA2 4653/4885CA7 4453/4885 |
| US-20150344497-A1 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO | JAK1, JAK2, JAK3 | CA1 4464/4885CA2 4653/4885CA7 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.